Note: The below is an edited version of an article originally published on BusinessWire.聽 The original article can be read in their entirety聽here.

The latest data from an ongoing Japanese Phase I/II study of Emicizumab were presented earlier this week at the World Federation of Hemophilia 2016 World Congress.聽 Emicizumab (a product being developed by Chugai Pharmaceutical Co., Roche, and Genentech) is a bispecific antibody for subcutaneous injection under development for hemophilia A.聽 The present study is an extension of a Phase I study investigating safety and exploratory prophylactic efficacy profiles of emicizumab in 18 Japanese hemophilia A patients both with and without FVIII inhibitors. The latest data analysis continued to show a promising profile of once-weekly subcutaneous injection of emicizumab in terms of safety and prophylactic efficacy, regardless of the presence of factor VIII inhibitors.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.